AmCad BioMed Corporation

AmCad BioMed Corporation is a Taiwan-based developer specializing in computer-assisted detection and diagnosis (CAD) medical devices. Established in 2008, the company’s primary focus is on leveraging artificial intelligence to create proprietary hardware and software solutions that enhance early disease detection and diagnostic accuracy for clinicians. Key product lines include CAD systems for thyroid cancer analysis, fatty liver, liver fibrosis, and obstructive sleep apnea, supported by FDA 510(k) and CE Mark certifications for multiple devices. These technologies are notable for integrating real-time sonographic visualization and quantification, enabling precise assessment through automated ultrasound and cytology imaging tools. AmCad’s innovations address significant unmet needs across healthcare, especially in diagnostic imaging for endocrine and respiratory disorders. The company’s ongoing commitment to R&D positions it as a significant player in advancing AI-powered medical diagnostics, with impactful applications in hospital, laboratory, and outpatient care sectors across the global healthcare market.